Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line

In the present study, we inspected the role of naringenin-loaded nanostructured lipid carriers (NLCs) in the induction of apoptosis in (HT-29) colon cancer cell in co-administration with oxaliplatin. The cytotoxicity behavior of nanoparticles was investigated by MTT assay and DAPI staining. To understand the molecular mechanism of formulation in induction program cell death, flow cytometric and Real-Time RT-PCR assays were applied. New formulation revealed a mean particle size of 98 +/- 3 nm with homogenous dispersity, which was confirmed by SEM graphs. Naringenin and Oxaliplatin-induced cell death in HT-29 colon cancer by IC50 value of 150 +/- 11.04 NM and 20 +/- 2.25 mu M, respectively. Loading Naringenin into new formulation declined the proportion of cell proliferation of HT-29 colon cancer from 47 +/- 9.1% to 27 +/- 5.3% (p < 0.05). Co-administration of naringenin loaded NLCs and oxaliplatin produced markedly increase the population of apoptosis from 31 +/- 2.3% up to 50 +/- 1.2% (p < 0.05). Gene expression profile revealed a substantial decrease in anti-apoptotic factors including survivin, cyclin-B1, and Nrf2 along with an increase in pro-apoptotic factor Bid mRNA expression. In conclusion, our data represented that naringenin-loaded NLCs can be introduced as a potential adjuvant to develop the efficacy of chemotherapy and decrease its high dose-dependent side effects.